Bristol-Myers Squibb Company (BMY) Q4 2019 Earnings Results

Bristol Myers Squibb Beats on EPS, Stock Up 2.3%

Bristol Myers Squibb's strong EPS performance indicates effective cost management and operational efficiency. The stock rose by 2.3%, reflecting investor confidence in the company's future prospects, despite the lack of revenue data and guidance. The positive surprise in EPS suggests that the company is on the right track, even as it navigates uncertainties in the market.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.22	N/A	+29.96%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management highlighted the strong EPS results as a positive sign. They emphasized their commitment to advancing their product pipeline.

Management expressed satisfaction with the EPS performance despite not providing revenue figures.

The focus remains on long-term growth and pipeline development.

Bristol Myers Squibb Beats on EPS, Stock Up 2.3%

Key numbers

Management commentary

Bristol-Myers Squibb Company

More earnings this week

Bristol Myers Squibb Beats on EPS, Stock Up 2.3%

Key numbers

Management commentary